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Modest decreases in endothelial 
NOS worsen diabetic nephropathy
Wang et al., Proc Natl Acad Sci USA 2011; 108: 2070–2075; doi:10.1073/
pnas.1018766108
About 30% of patients with diabetes will develop diabetic neph-
ropathy (DN), and the severity of the disease varies greatly 
among patients. Familial studies suggest that genetic factors 
are important in modulating the development and severity of 
DN. Nitric oxide (NO) generation by endothelial NO synthase 
(eNOS) has a critical role in maintaining cardiovascular and 
renal homeostasis, and eNOS inhibition worsens the phenotype 
of several cardiovascular and renal diseases; for example, com-
plete absence of eNOS accelerates DN in mice. In humans, three 
variants in the eNOS gene NOS3 are associated with DN, and 
5–9% of individuals are homozygous for one of these polymor-
phisms, G894T (Glu298Asp). Interestingly, in vitro, the 894T 
NOS3 gene produced about 30% of the NO produced by the 
more common 894G allele. To determine whether production of 
eNOS at reduced levels, rather than its complete absence, is suf-
ficient to worsen DN, Wang et al. first crossed C57BL/6J female 
eNOS+/− heterozygous mice with C57BL/6J males heterozygous 
for both the eNOS disruption (eNOS+/−) and the diabetogenic 
Akita mutation, a mutation of the insulin-2 gene that results 
in severe insulin deficiency. However, the inbred eNOS−/− and 
eNOS+/− diabetic males died before the age of 5 months and 
could not be studied. The authors next took advantage of the 
hybrid vigor of F1 mice, which were as genetically uniform 
as inbred mice but lacked most of the detrimental recessive 
mutations that affected the survival of the inbred parents. They 
crossed 129S6/SvEvTac inbred females heterozygous for the 
eNOS disruption (eNOS+/−) with C57BL/6 eNOS+/− hetero-
zygous inbred males that had the Akita mutation and studied 
the progeny. They found that the eNOS genotype in diabetic 
mice had the classical changes associated with DN and that they 
were progressively more severe, in this order: eNOS+/+ Akita < 
eNOS+/− Akita < eNOS−/− Akita (Figure). Some of these changes 
were probably due to increased blood pressure, but analysis of 
the data demonstrated that a modest decrease in eNOS, com-
parable to that associated with human NOS3 variants, was suf-
ficient to cause exacerbated DN independently of its effects on 
blood pressure.
Juan Oliver
NT5E mutations and  
arterial calcifications
St. Hilaire et al., N Engl J Med 2011; 364: 432–442; doi:10.1056/
NEJMoa0912923
Vascular calcification, arising in either the intima or the media 
of vessels, is associated with an excess risk of cardiovascular 
events and is the result of a process that mimics active bone 
remodeling. Only a single mendelian disorder of isolated vas-
cular calcification, generalized arterial calcification of infancy, 
has been described. St. Hilaire and colleagues conducted a study 
to evaluate an adult-onset disorder in three families whose 
affected members had extensive calcifications of the lower-
extremity arteries and small joint capsules and to investigate a 
possible genetic basis of the symptoms. Using elaborate meth-
odologies, they identified nine people with calcifications of the 
lower-extremity arteries and hand and foot joint capsules: all 
five siblings in one family, three siblings in another, and one 
patient in a third family. Serum calcium, phosphate, and vitamin 
D levels were normal. Affected members of Family 1 shared a 
single 22.4-Mb region of homozygosity on chromosome 6 and 
had a homozygous nonsense mutation (c.662C→A, p.S221X) in 
the NT5E gene, encoding CD73, a membrane-bound ecto-5ʹ-
nucleotidase (5ʹ-ribonucleotide phosphohydrolase; EC 3.1.3.5) 
that has AMP as preferred substrate converted to adenosine. 
Affected members of Family 2 had a homozygous missense 
mutation (c.1073G→A, p.C358Y) in NT5E. The proband of 
Family 3 was a compound heterozygote for c.662C→A and 
c.1609dupA (p.V537fsX7). All mutations found in the three 
families result in nonfunctional CD73. Cultured fibroblasts 
from affected members of Family 1 showed markedly reduced 
expression of NT5E mRNA, CD73 protein, and enzyme activity, 
as well as increased alkaline phosphatase levels and accumulated 
calcium phosphate crystals. Genetic rescue experiments nor-
malized the CD73 and alkaline phosphatase activity in patients’ 
cells, and adenosine treatment reduced the levels of alkaline 
phosphatase and calcification.
This important paper identifies mutations in NT5E in mem-
bers of three families with symptomatic arterial and joint 
Histology of F1 mice with different eNOS genotypes (eNOS
+/+, eNOS+/−, 
and eNOS−/−) and Akita mutation. Top: Periodic acid–Schiff stain. Yellow 
arrow indicates mesangial expansion; white arrows indicate mesangiolysis; 
yellow arrowhead indicates glomerulosclerosis. Middle: Glomeruli with 
Masson trichrome stain. Bottom: Transmission electron micrographs.
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calcifications. This gene encodes CD73, which converts AMP 
to adenosine, supporting a role for this metabolic pathway in 
inhibiting ectopic tissue calcification. The mechanism by which 
mineralization due to CD73 deficiency from an NT5E mutation 
occurs is shown in the figure.
Marc De Broe
Identification of adult nephron 
progenitors capable of kidney 
regeneration in zebrafish
Diep et al., Nature 2011; 470: 95–100; doi:10.1038/nature09669
Regeneration and formation of new nephrons in the failing kid-
neys would be the ideal solution for chronic kidney disease. 
Unfortunately, however, humans can only partly repair damaged 
nephrons and cannot form new ones after birth. By contrast, 
fish add nephrons throughout their lifespan and can regenerate 
nephrons de novo after injury, allowing experimental evalua-
tion of how new nephrons are generated. Therefore, Diep et al. 
traced the source of new nephrons and their regeneration after 
gentamicin injury in the adult zebrafish. They identified small 
intrarenal cell aggregates (10–30 cells) as nephron progenitors, 
which, upon transplantation into adult kidneys, were sufficient to 
generate multiple new and functional nephrons. These cells had 
characteristics consistent with stem cells. Elegant experiments 
with mixed, differentially labeled progenitors yielded mosaic 
nephrons, confirmed by live imaging showing nephron forma-
tion from multiple cells. Thus, the zebrafish kidney contains 
self-renewing nephron ‘stem/progenitor’ cells. Potentially, such 
cells may also exist in the human kidney, but their regeneration 
potential may be suppressed in humans. The identification and 
molecular characterization of these precursor cells in zebrafish 
should help in identifying and isolating the equivalent cells in 
mammals, including humans. This would represent a major 
advance in the as-yet utopian idea of growing new nephrons in 
failing kidneys and movement toward the dream of developing 
renal regenerative therapies for chronic kidney disease.
Detlef Schlöndorff
Prevention of dialysis catheter 
malfunction with recombinant 
tissue plasminogen activator
Hemmelgarn et al., N Engl J Med 2011; 364: 303–312; doi:10.1056/
NEJMoa1011376
Central venous dialysis access catheters are locked most commonly 
with heparin, although antibiotic, citrate, and thrombolytic solu-
tions have been used. Hemmelgarn et al. compared the effects of 
recombinant tissue plasminogen activator (rt-PA) and standard 
heparin as lock solutions on the outcomes of catheter malfunc-
tion and catheter-related bacteremia. Two hundred twenty patients 
were randomized to rt-PA (1 mg in each lumen) once a week at the 
midweek session, with unfractionated heparin (5000 U/ml) used 
at other sessions, or unfractionated heparin at all sessions. To be 
eligible for the study, patients had to have a tunneled catheter that 
had been newly inserted into their upper central venous system and 
could not be using systemic anticoagulant therapy or have had their 
catheter inserted by means of guidewire exchange. Patients were 
followed for 6 months after randomization. The primary outcome 
was catheter malfunction, defined as the first occurrence of peak 
blood flow of 200 ml/min or less for 30 minutes, mean blood flow 
of 250 ml/min or less during two consecutive dialysis treatments, or 
inability to initiate dialysis owing to inadequate blood flow. Twenty 
percent of patients in the rt-PA group and 34.8% of patients in the 
heparin group experienced the primary outcome (hazard ratio 1.91, 
95% confidence interval 1.13–3.22). Catheter-related bacteremia 
was defined as definite or probable according to previously pub-
lished criteria. The rates of catheter-related bacteremia were 0.40 
and 1.37 episodes per 1000 patient-days in the rt-PA and heparin 
groups, respectively. Bleeding was classified as fatal, major (a fall 
of 2.0 g/dl or requiring a transfusion of 2 or more units), clinically 
important (requiring admission or leading to an intervention), or 
minor (all other). Neither the frequency nor the severity of bleeding 
events differed between the groups. All four intracranial bleeding 
episodes (including one event that was fatal) were in the heparin 
group. Pharmacoeconomic analyses revealed that the incremental 
cost of caring for patients with rt-PA was Can$13,956 per episode 
of catheter-related bacteremia prevented.
This randomized trial demonstrates that locking solution with 
rt-PA prevents bacteremia as well as decreases the episodes of 
dysfunction. The pharmacoeconomic analyses conservatively 
present the cost of preventing bacteremia. The additional poten-
tial benefits of more adequate dialysis clearance as well as the 
potential mortality benefits, however, cannot be assessed. In the 
era of cost containment, this expense will need to be considered 
carefully. However, from the patient perspective, these data do 
not suggest a downside.
Lynda Szczech
On the surface of vascular cells, ENPP1 (the protein encoded by the 
ectonucleotide pyrophosphatase–phosphodiesterase 1 gene) converts 
ATP to AMP and pyrophosphate (PPi), and CD73 converts AMP to 
adenosine and inorganic phosphate (Pi). Pyrophosphate inhibits 
calcification, tissue-nonspecific alkaline phosphatase (TNAP) degrades 
pyrophosphate, and adenosine inhibits TNAP. Deficiency of CD73 
results in decreased adenosine levels, eliminating the inhibition of 
TNAP from the pathway either directly or by way of adenosine receptor 
signaling. Increased TNAP from the pathway activity results in decreased 
pyrophosphate and increased cell calcification.
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